within Pharmacolibrary.Drugs.ATC.J;

model J01DB10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 7.2 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,
    adminCount     = 1,
    Vd             = 0.0096,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Cefacetrile is a first-generation cephalosporin antibiotic, primarily used in veterinary medicine for the treatment of bacterial infections caused by susceptible Gram-positive and Gram-negative organisms. It has limited human use and is not currently approved for clinical use in humans in most countries.</p><h4>Pharmacokinetics</h4><p>Data for pharmacokinetics of cefacetrile in humans is scarce. Some estimates are available for parenteral (intravenous) use based on studies in animals and limited human data.</p><h4>References</h4><ol><li><p>Richards, DM, et al., &amp; Avery, GS (1984). Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. <i>Drugs</i> 27(6) 469–527. DOI:<a href=&quot;https://doi.org/10.2165/00003495-198427060-00001&quot;>10.2165/00003495-198427060-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6329638/&quot;>https://pubmed.ncbi.nlm.nih.gov/6329638</a></p></li><li><p>Colin, E, et al., &amp; Saint-Lorant, G (2020). Subcutaneously administered antibiotics. <i>Medecine et maladies infectieuses</i> 50(3) 231–242. DOI:<a href=&quot;https://doi.org/10.1016/j.medmal.2019.06.007&quot;>10.1016/j.medmal.2019.06.007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31300245/&quot;>https://pubmed.ncbi.nlm.nih.gov/31300245</a></p></li><li><p>Hartman, SJF, et al., &amp; de Wildt, SN (2022). Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children. <i>The Journal of antimicrobial chemotherapy</i> 77(6) 1725–1732. DOI:<a href=&quot;https://doi.org/10.1093/jac/dkac095&quot;>10.1093/jac/dkac095</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35383374/&quot;>https://pubmed.ncbi.nlm.nih.gov/35383374</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01DB10;
